⌕
Innoviva · INVA · Nasdaq
Tenet 73 · Solid
Compare
$18.49−2.84%At closeTenet 73 · Solid
$18.49−0.54 (−2.84%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Innoviva (INVA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 11, 2026 · 12:41 ET
Replenish Your Portfolio With These 5 Low Price-to-Sales Stocks

Low P/S ratios, solid fundamentals and manageable debt can help uncover undervalued stocks with upside potential. Explore INVA, DINO, PARR, GPRE and PBF.…

● Zacks Investment ResearchNov 10, 2026 · 10:41 ETEARNINGS EXPECTED BY FEB 22
Is Innoviva (INVA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

● Zacks Investment ResearchNov 9, 2026 · 12:41 ET
INVA or MRK: Which Is the Better Value Stock Right Now?

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?…

● Zacks Investment ResearchNov 4, 2026 · 20:52 ETEARNINGS EXPECTED BY FEB 22
Innoviva (INVA) Tops Q3 Earnings Estimates

Innoviva (INVA) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.08 per share a year ago.…

● Business WireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 22
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease pl…

● Business WireOct 19, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the In…

● Zacks Investment ResearchOct 12, 2026 · 12:16 ET
Do Options Traders Know Something About Innoviva Stock We Don't?

Investors need to pay close attention to INVA stock based on the movements in the options market lately.…

● Zacks Investment ResearchOct 8, 2026 · 12:40 ET
INVA vs. MRK: Which Stock Is the Better Value Option?

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors?…

● Zacks Investment ResearchOct 8, 2026 · 10:56 ET
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential

DINO, INVA, PARR, GNW and PBF stand out as low price-to-sales stocks with promising upside potential. Discover how attractive valuations can uncover hidden value.…

● Zacks Investment ResearchOct 8, 2026 · 10:41 ETEARNINGS EXPECTED BY FEB 22
Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

● Defense WorldSep 16, 2026 · 01:29 ET
Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Innoviva (NASDAQ: INVA - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based o…

● Defense WorldSep 15, 2026 · 03:29 ETEARNINGS EXPECTED BY FEB 22
Baird Financial Group Inc. Makes New $6.23 Million Investment in Innoviva, Inc. $INVA

Baird Financial Group Inc. acquired a new stake in Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutiona…

● GuruFocusSep 2, 2026 · 09:00 ET
Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical…

● Defense WorldSep 2, 2026 · 04:59 ETEARNINGS EXPECTED BY FEB 22
Hsbc Holdings PLC Buys Shares of 49,428 Innoviva, Inc. $INVA

Hsbc Holdings PLC acquired a new position in Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 49,428 shares of the biotechnol…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.